DELCATH SYSTEMS, INC. (DCTH) - Dilution Analysis

10-Q filing | 36.0M shares outstanding

10-Q filing | 36.4M shares outstanding

10-Q filing | 35.8M shares outstanding

10-Q filing | 34.6M shares outstanding

10-K filing | 33.4M shares outstanding

10-Q filing | 32.3M shares outstanding

POS AM filing: This prospectus relates to the re-sale by the selling stockholders of up to an aggregate of 2,762,657 shares of common stock issuable upon conversion of preferred stock and exercise of warrants.

POS AM filing: This prospectus relates to the offer and sale by us of an aggregate 1,851,900 of our shares of common stock that are issuable at an exercise price of $10.00 per share upon exercise of the currently outstanding series F warrants and 17,456 shares of Common Stock that are issuable at an exercise price of $0.01 per share upon exercise of the currently outstandingpre-funded warrants.

10-Q filing | 28.4M shares outstanding

S-3 filing: The company is filing an S-3 to offer shares of its common stock, preferred stock, debt securities, and warrants and units to purchase any of such securities, up to a total aggregate offering price of $150,000,000.

10-Q filing | 27.8M shares outstanding

S-3/A filing: This is an S-3/A amendment filing for Delcath Systems, Inc., indicating a delayed or continuous offering pursuant to Rule 415 under the Securities Act of 1933.

S-3 filing: This prospectus relates to the offer and resale of 1,918,140 shares of the Company’s common stock by the selling stockholders.

10-K filing | 24.6M shares outstanding

10-Q filing | 22.0M shares outstanding

10-Q filing | 15.3M shares outstanding

S-3 filing: This S-3 filing relates to the offer and resale of up to 19,509,749 shares of the Company’s Common Stock by the selling stockholders.

10-Q filing | 11.6M shares outstanding

10-K filing | 10.1M shares outstanding

S-3 filing: This prospectus relates to the resale from time to time by the Selling Stockholders identified in this prospectus of up to 2,140,931 shares of the Company 92s Common Stock, which consist of (i) 1,448,889 shares of Common Stock held by the Selling Stockholders and (ii) 692,042 shares of Common Stock (the 93Warrant Shares 94 and together with the Shares, the 93Securities 94) issuable upon the exercise of pre-funded warrants held by the Selling Stockholders.

10-Q filing | 9.2M shares outstanding

S-3 filing: This S-3 filing relates to the resale from time to time by the Selling Stockholders of up to 1,257,705 shares of the Company’s Common Stock, which consist of (i) 690,954 shares of Common Stock held by the Selling Stockholders and (ii) 566,751 shares of Common Stock issuable upon the exercise of pre-funded warrants held by the Selling Stockholders.

10-Q filing | 8.2M shares outstanding

10-Q filing | 7.9M shares outstanding

10-K filing | 7.9M shares outstanding

10-Q filing | 7.6M shares outstanding

S-3 filing: This is an S-3 filing for the offering of common stock by selling stockholders, including shares issuable upon conversion of preferred stock and warrants.

10-Q filing | 6.7M shares outstanding

8-K filing: Delcath Systems, Inc. reports an increase in outstanding shares of common stock due to the conversion of Series E and E-1 Convertible Preferred Stock, the exercise of Series F, E, and E-1 warrants, and the exercise of pre-funded warrants as of June 28, 2021.

S-3 filing: The company is filing an S-3 to register up to $100 million in aggregate principal amount of our common stock, preferred stock, debt securities, warrants and/or units in one or more offerings.

10-Q filing | 6.5M shares outstanding

10-K filing | 6.3M shares outstanding

8-K filing: As of February 23, 2021, Delcath Systems, Inc. had 6,249,307 shares of common stock issued and outstanding. The increase in outstanding shares is due to the conversion of preferred stock, exercise of warrants, and issuance of common stock in lieu of cash payment of director fees.

10-Q filing | 4.3M shares outstanding

8-K filing: Delcath Systems, Inc. reports an increase of more than 5% in outstanding shares of common stock as of October 15, 2020, reaching 4,090,249 shares due to conversions of Series E preferred stock, exercise of Series F warrants, and purchases in an at-the-market offering.

10-Q filing | 3.9M shares outstanding

8-K filing: Delcath Systems, Inc. reports an increase in outstanding common stock by more than 5% due to the conversion of Series E and E-1 Convertible Preferred Stock into 372,500 shares of Common Stock and the conversion of a pre-funded warrant to purchase 6,000 shares of Common Stock.

10-Q filing | 2.8M shares outstanding

8-K filing: The Company consummated an underwritten public offering of 1,823,000 shares of common stock, pre-funded warrants to purchase up to 377,000 shares of common stock, and Series F warrants to purchase 2,224,900 shares of common stock.

S-1/A filing: This S-1/A filing relates to the re-sale by selling stockholders of 1,455,775 shares of common stock of Delcath Systems, Inc.

S-1/A filing: This S-1/A filing relates to the re-sale of 569,100 shares of common stock by selling stockholders and a proposed public offering for listing on the NASDAQ Capital Market.

S-1/A filing: This is an S-1/A filing for an offering of common stock, Series F warrants, and pre-funded warrants with Roth Capital Partners, Aegis Capital Corp., and Laidlaw & Company (UK) Ltd. as underwriters. The company intends to use the net proceeds of this offering for working capital and general corporate purposes, including the continued development of Melphalan/HDS.

10-K filing | 0.1M shares outstanding

S-1/A filing: This S-1/A filing relates to an offering of common stock and pre-funded warrants with Roth Capital Partners and Aegis Capital Corp. acting as book-running managers. The company intends to use the net proceeds for working capital and general corporate purposes, including the continued development of Melphalan/HDS.

S-1 filing: This S-1 filing relates to the resale of 1,882,723 shares of common stock by selling stockholders.

S-1 filing: The company is offering $25,000,000 of shares of common stock in this offering and intends to use the net proceeds of this offering for working capital and general corporate purposes, including the continued development of Melphalan/HDS.

S-1/A filing: This prospectus relates to the re-sale by the selling stockholders of up to an aggregate of 3,429,680 shares of common stock of Delcath Systems, Inc.